Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.
Under the deal, Clinical Ink's investor syndicate is laying out an undisclosed sum to bring in CentrosHealth and its software for designing, reviewing and launching mobile apps for clinical trials. MPM Capital and F2 Ventures joined previous Clinical Ink backer FCA Venture Partners to bring about the merger, betting the two companies can combine to create a singular offering for sponsors, CROs and research sites.
 |
| Clinical Ink CEO Ed Seguine |
Separately, Novartis ($NVS) has entered into a partnership with Clinical Ink as part of its Trials of the Future program, an effort to encourage the adoption of paperless study protocols. That co-sign serves as a validation of the merger's potential, Clinical Ink CEO Ed Seguine said, and the combined company believes its technology can improve patient engagement.
"The combination of Clinical Ink and CentrosHealth backed by the deep expertise, relationships, and financial resources of MPM Capital creates a powerful opportunity to transform the clinical development business model," Seguine said in a statement. "This multi-part transaction underscores the tremendous progress we've made and the future potential for our combined businesses to deliver innovative technology solutions that eliminate the root causes of clinical trial inefficiency."
- read the statement